12
Participants
Start Date
August 31, 2010
Primary Completion Date
October 31, 2011
Study Completion Date
October 31, 2011
PF-04427429
Single dose IV infusion up to 300mg
Capsaicin challenge
Capsaicin challenge: 110 mg (0.075% capsaicin) to be applied at pre-dose and at 2h, 5h, 8h and 24h post-dose as well as 1 week and 4 weeks post final treatment period
Placebo
Placebo IV infusion (saline) to be administered during two of the three treatment periods
Capsaicin challenge
Capsaicin challenge: 110 mg (0.075% capsaicin) to be applied at pre-dose and at 2h, 5h, 8h and 24h post-dose as well as 1 week and 4 weeks post final treatment period
EMLA positive control
2g EMLA cream to be applied ONCE during study period 1
Pfizer Investigational Site, Brussels
Lead Sponsor
Pfizer
INDUSTRY